Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 27

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 27
---
 to convince physicians of the benefits of our proposed diagnostic tests or therapeutic products, we may incur delays or additional expense in our attempt to establish market acceptance.

Broad use of our proposed diagnostic tests and products
may require pathology laboratories and physicians to be informed regarding our proposed diagnostic tests and products and their intended
benefits. Inability to carry out this physician education process may adversely affect market acceptance of our proposed diagnostic tests
or therapeutic products. We may be unable to timely educate physicians regarding our proposed diagnostic tests or therapeutic products
in sufficient numbers to achieve our marketing plans or to achieve acceptance of our diagnostic tests or therapeutic products. Any delay
in physician education may materially delay or reduce demand for our diagnostic tests or therapeutic products. In addition, we may expend
significant funds toward physician education before any acceptance or demand for our proposed diagnostic tests or therapeutic products
is created, if at all.

We face substantial competition, which may result in others discovering, developing, or commercializing competing diagnostic tests or therapeutic products before or more successfully than we do.

The development and commercialization of new diagnostic
and therapeutic technologies is highly competitive. We will always face competition with respect to any diagnostic and therapeutic technology
that we may seek to develop or commercialize in the future from major diagnostic and pharmaceutical companies, LDT laboratories, smaller
diagnostic and pharmaceutical companies, and biotechnology companies worldwide.

A substantial number of the companies against which
we are competing or may compete against in the future may have significantly greater financial resources, established presence in the
market, and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory
approvals, and marketing approved diagnostic tests or therapeutic products. Mergers and acquisitions in the diagnostic, pharmaceutical,
and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors.

Smaller and other early-stage companies may also prove
to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties
compete with us in recruiting and retaining qualified scientific, sales, marketing, and management personnel, establishing clinical trial
sites and patient registration for clinical trials, and acquiring technologies complementary to or necessary for our programs.

Our commercial opportunity could be reduced or eliminated
if our competitors develop and commercialize diagnostic tests or therapeutic products that are more accurate, more convenient, or less
expensive than any diagnostic tests or therapeutic products that we may develop. Our competitors also may obtain FDA or other regulatory
approval for their diagnostic tests or therapeutic products more rapidly than we may